caprotec bioanalytics GmbH, a Berlin, Germany-based developer of a technology for analyzing complex protein mixtures, closed a €4m (approximately $5.1m) Series B financing round.
Investors in the round include existing partners Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and other private investors.
The financing will enable the company to further develop and commercialize its proprietary CCMS (Capture Compound Mass Spectrometry) platform technology for analyzing complex protein mixtures, which was developed by Prof. Dr. Hubert Koster, founder and CEO of caprotec bioanalytics GmbH.
In particular, the proceeds will be used to further develop caproKits™ as tools for the worldwide R&D community to identify functionally selected protein classes and the company’s ImproMed™ application to profile drug-protein interactions, generating the information to structurally optimize the drug molecule for increasing efficacy and reducing adverse side effects.
caprotec bioanalytics also operates a US subsidiary in Burlington, MA.